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Abstract
Background and Purpose: Because of the high success of laparoscopic pyeloplasty (LP) for ureteropelvic junction
obstruction, strategies for managing failures are less well described. We report our experience with persistent or
recurrent obstruction after LP.
Patients and Methods:We reviewed 128 patients who were treated with LP at our institution from 1996 through
2008. Success was defined as objective resolution of obstruction by renal scintigraphy, Whitaker testing, or direct
visualization. We extracted data by chart review regarding patient demographics, medical history, operative
technique, and salvage treatments. We then assessed for association between patient characteristics and treat-
ment failure.
Results: Overall, 102 patients had sufficient follow-up, of which 84 (82%) were successes. Of 18 failures, median
time to failure was 2.5 months (0.5–88mos). Of 10 failures managed endoscopically, 7 were salvaged. One of two
patients treated conservatively ultimately had resolution while six patients needed simple nephrectomy. Overall,
8 (44%) were salvageable with median follow-up of 19 months (4–58mos). Patients with failure were more likely
to have diabetes mellitus, longer length of stay, higher American Society of Anesthesiologists (ASA) score, a
stent placed at the time of pyeloplasty, or ureteral stent malfunction (P < 0.05). Patients with failure despite
salvage were more likely to have stent malfunction or body mass index > 30 kg/m2 (P < 0.05). Adjusting for the
above factors, stent placement at time of surgery and ASA score > 2 were associated with failure (P < 0.05) while
periureteral fibrosis trended toward a significant association (P = 0.061).
Conclusion: Nearly half of failures after LP are salvageable, many with endoscopic management.
Introduction
Laparoscopic pyeloplasty (LP) for ureteropelvic junctionobstruction (UPJO) was first described in 1993.1 Although
technically challenging, LP is associated with high success
rates, ranging from 84% to 98%.2–5 LP achieves better success
rates than endopyelotomy (EP) and comparable results to
open pyeloplasty (OP).3,6More recently, robot-assisted LP has
gained ground with outcomes equivalent to those of con-
ventional LP.7 Given the benefits of easier convalescence,
decreased pain, and smaller incisions,6 LP (both conventional
and robot-assisted) is now considered the standard of care for
UPJO at many institutions.4,8
Despite the high success rates, some patients have persis-
tent or recurrent UPJO. Various strategies have been used in
these situations: Observation, ureteral stent placement, or
percutaneous nephrostomy, EP, repeated LP, OP, or ne-
phrectomy. While secondary procedures have been reported
in some series,3,7,9 data available on salvage strategies and
subsequent outcomes are lacking. LP and EP have been both
described as salvage therapy for failed pyeloplasty with good
results, but these have been primarily after open surgery.10–12
Furthermore, potentially modifiable risk factors that are as-
sociatedwith recurrent or persistent obstruction after primary
and secondary repair have not been well described.
To gain better insight on the salvage setting, we analyzed
our series of patients who were treated with LP to determine
failure and success rates. We describe our management
strategies for salvage therapy and report our overall out-
comes. We also attempt to identify potentially modifiable risk
factors associatedwith persistent or recurrent obstruction that
may help urologists minimize failures after laparoscopic re-
pair.
Patients and Methods
Data source and subjects
Institutional Review Board approval was obtained to per-
form a retrospective review of patients who were undergoing
LP at the University of Michigan. We identified 128 patients
from August 1996 through September 2008. In general,
UPJO was diagnosed by diuretic renal scan (DRS) and then
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confirmed by retrograde pyelography at the time of LP. In
four patients, diagnosis was confirmedwithWhitaker testing,
in three patients for equivocal DRS findings and in 1 because a
nephrostomy tube was already in place. A ureteral stent was
placed cystoscopically either before LP or at the time of sur-
gery. All LPs were performed transperitoneally, as described
previously.13 A closed suction drain was placed and removed
before discharge unless a urine leak was suspected. The ure-
teral stent was routinely removed between 2 and 6 weeks
postoperatively followed by DRS obtained at 3 weeks, 3
months (if the 3-week result was equivocal), 1 year after stent
removal, and variably thereafter. Patients lost to follow-up
after stent removal (10) or who opted for local follow-up (14)
were excluded. There were two intraoperative conversions to
OP, and these patients were excluded from the analysis.
Primary outcome
We assessed our patients for success or failure both before
and after salvage attempt.Wedefined success asDRSwith T½
£ 20 minutes, accompanied by improvement in symptoms. In
cases where the DRS result was either equivocal or discordant
with the clinical picture (ie, elevated T½ with resolution of
symptoms or vice versa), success was defined by negative
Whitaker testing (pressure gradient < 20 cmH2O) or patency of
the UPJ on direct ureteroscopic visualization (except in three
patients described in the Results section). Remaining cases
were deemed failures. Rates of success, success including sal-
vage, failure, and failure despite salvage were calculated. The
numerators were number of successes or failures before and
after salvage attempt. Thedenominatorwas number of patients
receiving LP with adequate follow-up, as described above.
Statistical analysis
A detailed chart review was performed of each case. We
extracted data on patient demographics, primary surgeon,
surgeon experience, body mass index (BMI), infection, uro-
lithiasis history, surgical history, DRS and radiographic
findings, need for urinary diversion, and previous treatment
for UPJO. Charlson comorbidity index (CCI) was calculated
for each patient.14 Intraoperative factors, including American
Society of Anesthesiologists (ASA) score, estimated blood
loss, operative time, preoperative stent vs stent placed at time
of surgery, type of repair, crossing vessel, and periureteral
fibrosis, were also recorded. Finally, we assessed patients for
postoperative complications (eg, any, urine leak, stent mal-
function), duration of follow-up, and management of failures
(ie, conservative, endoscopic [eg, balloon dilation, EP], LP,
OP, and nephrectomy).
Failures and failures despite salvage were compared with
successes with bivariable analyses using parametric or non-
parametric testing as appropriate. We then fit a multivariable
logistic regression model with potentially modifiable factors
identified a priori or through bivariable analyses. For all sta-
tistical inferences, we performed two-sided significance test-
ing and set a type I error rate at 0.05, using the SAS system
(v9.2, SAS Institute, Cary, NC).
Results
Of 128 cases, 102 were available for review. Overall, we
identified 84 (82%) successes and 18 (18%) failures. This in-
cludes three patients (including one patient who underwent
bilateral LPs for horseshoe kidney) we considered to have
successful outcomes despite abnormal DRS findings because
of complete resolution of pain along with additional evidence
of functional improvement (ie, significant reduction in serum
creatinine level in two patients and complete resolution of
hydronephrosis in the other). Conversely, there were three
patients we considered to be failures because they needed an
intervention for persistent symptoms despite a DRS T½ £ 20
minutes. Of the 18 failures, median time to failure was 2.5
months (0.5–88mos). Five patients presented more than 1
year post-LP while 13 patients presented within the first year
of surgery. Of these patients, 11 demonstrated evidence of
obstruction within the first 3 months postoperatively.
Management of failed LP is detailed in Figure 1. Two pa-
tients opted for conservative management, one of whom ex-
perienced spontaneous resolution. Seven of 10 patients had
successful salvage endoscopically. Of the three patients in
whom EP failed, two patients underwent salvage OP: One
had persistent obstruction while the other had initial resolu-
tion before recurrent obstruction developed 4 years later. Six
patients needed simple nephrectomy. These patients dem-
onstrated severe symptoms because of their UPJO (n = 5),
significant obstruction (DRS T½ > 99min, n= 2), and/or
poorly functioning kidney (post-LP DRS differential < 5%,
n = 3), and were thought to have a significantly low proba-
bility of successful salvage. Overall, salvage occurred in 8
(44%) patients (median follow-up postsalvage of 19 months
[4–58 months]), resulting in 92 (90%) successes including
salvage and 10 (10%) failures despite salvage.
The results of our bivariable analyses are reported in Table
1. Comparing successes with both failures and failures despite
salvage, we found no significant differences in age, sex, CCI,
previous urinary diversion, previous EP, type of repair,
periureteral fibrosis, or crossing vessel. Although not in-
cluded in Table 1, we also found no significant association
between failure and side of UPJO, surgical history, primary
surgeon, and surgeon experience (all P values > 0.40). Patients
who experienced failure were more likely to have diabetes
mellitus, a longer length of stay, higher ASA score, a stent
placed at time of pyeloplasty, and ureteral stent malfunction
(P< 0.05). Patients who experienced failure despite salvage
weremore likely to have stentmalfunction or BMI > 30 kg/m2
(P< 0.05). While the frequency of urine leaks and complica-
tions overall were similar, patients in whom LP failed were
more likely to experience a stent malfunction. Notably, seven
of eight patients with stent malfunction returned to the op-
erating room for stent adjustment, change, or removal.
As described in Table 2, stent placement at the time of
surgery and ASA score > 2 were both associated with failure
on our multivariable analysis (P < 0.05). While neither diabe-
tes mellitus nor BMI > 30 kg/m2 were found to be associated
with failure, periureteral fibrosis trended toward a significant
association with persistent or recurrent UPJ obstruction
(P= 0.061). In contrast, there was no association with these
factors and failure despite salvage after adjusting for factors
identified a priori or through bivariable analyses (Table 2).
Discussion
At our institution, LP is associated with an 82% success
rate. Nearly half of our failures were salvageable, most with
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conservative management or endoscopic repair. Salvage OP
was attempted in two with mixed results. One-third of pa-
tients who experienced failure received a simple nephrec-
tomy, many of whom had been counseled about simple
nephrectomy for poorly functioning kidney but elected to
proceed with an attempted reconstruction. When comparing
successes with failures, patients who had failure were more
likely to have diabetes mellitus, longer length of stay, higher
ASA score, stent placement at time of pyeloplasty, or ureteral
stent malfunction. Patients with failure despite salvage were
more likely to have a stent malfunction or body mass index
> 30 kg/m2. On multivariable analysis, stent placement at
time of pyeloplasty and ASA score > 2 were associated with
failure while periureteral fibrosis trended toward signifi-
cance.
Our success rate is slightly lower than previously published
series.2–4,7,15 We did exclude 24 patients who were followed
locally or lost to follow-up. Because it is likely that these pa-
tients would re-present or be rereferred if clinical evidence of
recurrent UPJO developed, our true success rate may be
higher. In addition, success rates may, in fact, be lower than
previously thought. As seen in our series, many failures occur
beyond 1 year after surgery, necessitating the need for longer
follow-up.5,13,16 Moreover, success rates vary according to
definition,17 and standardized definitions of success after re-
pair of UPJO may allow for better comparisons between se-
ries.
As demonstrated by our series, a variety of treatment
strategies can be used for the management of recurrent or
persistent obstruction after LP. Our findings appear to be
consistent with previously published reports (Table 3). En-
doscopic management produces fair results and appears to be
the most common surgical technique.3,7,9 More recently, there
have been a few reports of LP as salvage therapy after an
initial LP because of the promising results achieved with LP
after previously failed OP.7,9–11 Given the likelihood of sig-
nificant fibrosis and good results noted with OP in secondary
obstruction,12,18–20 we opt for the open approach when pa-
tients experience failure with both LP and EP. While we have
had good success with OP for secondary UPJO, our results
have beenmixed after recurrent or persistent obstruction after
LP. Interestingly, conservative management may be an in-
creasingly viable option, especially in patients with minimal
symptoms and stable renal function.4,5 Overall, many patients
can have salvage with conservative management or endo-
scopic repair after failure of LP.
FIG. 1. Management of recurrent or persistent obstruction after laparoscopic pyeloplasty at the University of Michigan,
including salvage treatments attempted and outcomes.
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Given the variable salvage rates and need for subsequent
procedures, the best management of failure may be pre-
vention. To date, risk factors for persistent or recurrent
obstruction after LP have not been well defined. Hydro-
nephrosis, poor renal function, and crossing vessel have
been identified as risk factors for EP while ASA score and
BMI have been associated with complications of urologic
laparoscopy.18,21–23 Based on our analysis, higher ASA score
and obesity may be specific risk factors for failure after LP.
Perhaps more interesting is the potential relationship be-
tween diabetes mellitus and failure after LP. It has been
hypothesized that diabetes-related microvascular disease
negatively impacts a healing anastomosis because diabetes
mellitus has been linked to poorer outcomes in procedures
that involve reconstruction of the urinary tract.24–26 Unlike
ASA score and obesity, diabetes may be more modifiable in
Table 1. Bivariable Analyses —Failures and Failures Despite Salvage Compared to Successes
and Successes Including Salvage, Respectively
Success (%) Failure (%) P value Success including salvage (%) Failure after salvage (%) P value
No. of patients 84 18 92 10
Age (years)# 35.2 – 14.6 36.9 – 15.9 0.672 35.7 – 15.2 33.9 – 10.7 0.645
Male 51.2 44.4 0.796 50.0 50.0 1.000
BMI > 30 kg/m2 12.2 27.8 0.138 12.2 40.0 0.041
Diabetes 3.6 22.2 0.017 5.4 20.0 0.139
Infection 23.8 11.1 0.348 23.9 0.0 0.113
Stone history 17.9 33.3 0.196 18.5 40.0 0.209
CCI 0 66.7 66.7 1.000 67.4 60.0 0.417
CCI 1 14.3 16.7 13.0 30.0
CCI 2 or more 19.1 16.7 19.6 10.0
Urinary diversion 63.1 61.1 0.874 62.0 70.0 0.617
Previous EP 20.2 22.2 1.000 19.6 30.0 0.426
DRS < 35%a 28.9 25.0 1.000 25.0 50.0 0.206
DRS T½ > 20mina 75.4 75.0 1.000 75.8 71.4 1.000
OR time (min)b 199.8– 57.7 213.8– 84.3 0.510 198.1– 56.2 239.4– 103.6 0.244
LOS (days)b 2.4 – 1.1 3.2 – 1.5 0.046 2.4 – 1.1 3.4 – 1.8 0.124
EBL (mL)b 73.1 – 60.2 73.2 – 30.0 0.992 72.7 – 58.1 79.5 – 33.8 0.666
ASA 1 54.8 38.9 0.045 54.4 30.0 0.074
ASA 2 42.9 44.4 42.4 50.0
ASA 3+ 2.4 16.7 3.3 20.0
Stent at time of LP 61.9 88.9 0.030 64.1 90.0 0.159
Dismembered 77.4 72.2 0.640 77.2 70.0 0.612
Simple ND 21.4 22.2 1.000 21.7 20.0 1.000
Complex repair 1.2 5.6 0.323 1.1 10.0 0.187
Crossing vessel 63.1 55.6 0.599 64.1 40.0 0.176
Fibrosis 25.0 44.4 0.147 27.2 40.0 0.464
Any complication 31.0 50.0 0.122 31.5 60.0 0.072
Urine leak 17.9 16.7 1.000 17.4 20.0 1.000
Stent complication 4.8 22.2 0.031 5.4 30.0 0.030
aPreoperative DRS findings.
bContinuous variables are presented as mean– standard deviation.
BMI= body mass index; CCI=Charlson comorbidity index; EP= endopyelotomy; DRS=diuretic renal scan; OR= operating room;
LOS= length of stay; EBL= estimated blood loss; ASA=American Society of Anesthesiologists; LP= laparoscopic pyeloplasty; ND=
nondismembered repair.
Table 2. Multivariable Analysis —Failure And Failure Despite Salvage
Failure Failure after Salvage
Variable Odds ratio (95% CI) P value Odds ratio (95% CI) P value
ASA 2 vs. 1 0.99 (0.27–3.58) 0.988 1.57 (0.31–8.05) 0.585
ASA 3+ vs. 1 20.92 (1.10–399.36) 0.043 12.72 (0.56–286.89) 0.110
BMI > 30 kg/m2 1.01 (0.20–5.20) 0.989 2.16 (0.36– 12.84) 0.397
Diabetes mellitus 3.61 (0.53–24.48) 0.189 1.11 (0.12–10.41) 0.927
Fibrosis 3.19 (0.95–10.74) 0.061 1.94 (0.43–8.76) 0.391
Stent at time of LP 12.50 (1.38–113.00) 0.025 8.28 (0.66–104.14) 0.102
CI= confidence interval; ASA=American Society of Anesthesiologists; BMI= body mass index; LP= laparoscopic pyeloplasty.
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terms of preoperative and perioperative management.
General guidelines have been developed regarding the
management of hyperglycemia and diabetes around the
time of surgery.27
Repair of UPJO may be more technically challenging in the
salvage setting because of fibrosis and inflammation. While
there are multiple etiologies for fibrosis (eg, infection, previ-
ous instrumentation, previous abdominal surgery), signifi-
cant fibrosis has been observed during both laparoscopic and
open surgery after previous EP.11,18–20 While we did not
identify EP as a risk factor for failure, lower success rates have
been reported with LP for secondary UPJO,2,5 and prelimi-
nary findings from a larger multi-institutional study have
identified previous EP as a potential risk factor for failure after
robot-assisted and conventional LP.28 Steps to minimize fi-
brosis, including altering our practice patterns with respect to
EP, may decrease the occurrence of failures after pyeloplasty.
Our findings must be considered in the context of several
limitations. As a retrospective analysis, we are vulnerable to
potential confounders. In fact, we found stent placement at
the time of pyeloplasty to be associated with failure even
though the disadvantages of a preplaced stent (eg, decom-
pressed collecting system, risk of displacement or damage,
inflammation, edema) have beenwell described.2,29 Given the
association between postoperative stent malfunction and
failure in our series, stent placement practices may play a
larger role in affecting the outcome after LP and may deserve
further study. It is just as plausible, however, that patients
with a stent in place may be predisposed toward success for
other reasons. For example, they may be more symptomatic
or have more severe obstruction.
Next, we may be underpowered to identify certain factors
associated with failure after LP despite comparable size to
other series. A larger, multi-institutional study as mentioned
above was able to identify EP as a risk factor, and it may be
more generalizable given the larger cohort size. Our more
complete dataset, however, enables us to examine other
clinical factors more precisely. Despite this advantage, we
were still unable to incorporate specific renal scan parameters
or degree of hydronephrosis in our analyses because of vari-
ations in interpretation of imaging studies; many of these
were from outside institutions. These objective measures may
provide additional information in future assessments of UPJO
and its surgical management.
These limitations notwithstanding, our findings have po-
tential implications on the management of UPJO. The major-
ity of practicing urologists currently use EP as initial therapy
for primary UPJO despite lower rates of success when com-
pared with pyeloplasty.3,5,8,16 Given the association of failure
with fibrosis and potentially EP, EP should be used conserva-
tively in the primary setting and may be better used as salvage
therapy for recurrent UPJO.3,30 Presence of a crossing vessel,
marked hydronephrosis, and previous failed EP appear to af-
fect treatment selection for UPJO among practicing urologists.8
Based on our findings, ASA score, BMI, and diabetes mellitus
should also be considered. Given the good success rates of LP,
incorporating these factors into the decision-making may fur-
ther minimize an already low failure rate after LP. If failure
should occur, conservative options such as observation or en-
doscopic management are likely to yield good results.
Conclusion
LP is now the standard of care for UPJO at many institu-
tions. Although uncommon, failures can occur but are often
manageable with conservative or minimally invasive tech-
niques. Stent placement at time of LP, fibrosis, ASA score,
obesity, and diabetes mellitus may impact the outcome of LP.
Consideration of these factors during decision-making may
help minimize the occurrence of failures after LP.
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